Custom Antibody Production Services
By Biotechdaily staff writers
Posted on 05 Sep 2002
Custom antibody and recombinant protein production services are being offered by Fusion Antibodies Ltd. (Belfast, Northern Ireland) to pharmaceutical, biotechnology, and academic customers. Posted on 05 Sep 2002
The company uses proprietary technology to rapidly produce fusion proteins from genes supplied by clients, using a process based on the company's high-throughput platform that identifies protein fragments from a large number of expression clones. These products can be used as antigens for the production of polyclonal and monoclonal antibodies. The company says it can supply antibodies with 100% efficacy, compared to the current 10-20% efficacy of products manufactured using peptide antigens.
Fusion is developing therapeutic antibodies to treat breast, brain, colorectal, and liver cancer. The company has identified specific surface receptors that are shown to be both unique to these tumors and expressed at later stages in cancer development. In addition, Fusion has a number of targets amenable to monoclonal therapy in various disease states.
The company has established major collaborations with institutes in Europe, Brazil, Singapore, and the US and has clients from academic institutes around the world.
Related Links:
Fusion Antibodies Ltd.
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Gel Cards
DG Gel Cards
Automatic Hematology Analyzer
DH-800 Series
